[1] |
Sciuto R, Romano L, Rea S, et al.
Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution[J]. Ann OncolAnn Oncol, 2009, 20(10): 1728-1735.
doi: 10.1093/annonc/mdp050
|
[2] |
Muresan MM, Olivier P, Leclère J, et al.
Bone metastases from differentiated thyroid carcinoma[J]. Endocr Relat CancerEndocr Relat Cancer, 2008, 15(1): 37-49.
doi: 10.1677/ERC-07-0229
|
[3] |
Mihailovic JM, Stefanovic LJ, Malesevic MD, et al.
Metastatic differentiated thyroid carcinoma: clinical management and outcome of disease in patients with initial and late distant metastases[J]. Nucl Med CommunNucl Med Commun, 2009, 30(7): 558-564.
doi: 10.1097/MNM.0b013e32832cc2ab
|
[4] |
Durante C, Haddy N, Baudin E, et al.
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy[J]. J Clin Endocrinol MetabJ Clin Endocrinol Metab, 2006, 91(8): 2892-2899.
doi: 10.1210/jc.2005-2838
|
[5] |
Schlumberger M, Tubiana M, De Vathaire F, et al.
Long-term results of treatment of 283 patients with lung ang bone metastases from differentiated thyroid carcinoma[J]. J Clin Endocrinol MetabJ Clin Endocrinol Metab, 1986, 63(4): 960-967.
doi: 10.1210/jcem-63-4-960
|
[6] |
Sugitani I, Fujimoto Y, Yamamoto N, et al.
Papillary thyroid carcinoma with distant metastases: survival predictors and the importance of local control[J]. SurgerySurgery, 2008, 143(1): 35-42.
doi: 10.1016/j.surg.2007.06.011
|
[7] |
Baitei EY, Zou M, Al-Mohanna F, et al.
Aberrant BRAF splicingas an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma[J]. J PatholJ Pathol, 2009, 217(5): 707-715.
doi: 10.1002/path.2496
|
[8] |
Kogai T, Sajid-Crockett S, Newmarch LS, et al.
Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells[J]. J EndocrinolJ Endocrinol, 2008, 199(2): 243-252.
doi: 10.1677/JOE-08-0333
|
[9] |
Ahn SH, Henderson Y, Kang Y, et al.
An orthotopic model of papillary thyroid carcinoma in athymic nude mice[J]. Arch Otolaryngol Head Neck SurgArch Otolaryngol Head Neck Surg, 2008, 134(2): 190-197.
doi: 10.1001/archoto.2007.36
|
[10] |
Younes MN, Kim S, Yigitbasi OG, et al.
Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer[J]. Mol Cancer TherMol Cancer Ther, 2005, 4(8): 1146-1156.
doi: 10.1158/1535-7163.MCT-05-0078
|
[11] |
Schweppe RE, Kerege AA, Sharma V, et al.
Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells tomitogen-activatedproteinkinase kinase 1/2 inhibition[J]. ThyroidThyroid, 2009, 19(8): 825-835.
doi: 10.1089/thy.2008.0362
|
[12] |
Cheng SP, Yin PH, Chang YC, et al.
Differential roles of leptin in regulating cell migration in thyroid cancer cells[J]. Oncol RepOncol Rep, 2010, 23(6): 1721-1727.
|
[13] |
Schweppe RE, Klopper JP, Korch C, et al.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contaminationresultingincelllineredundancyand misidentification[J]. J Clin Endocrinol MetabJ Clin Endocrinol Metab, 2008, 93(11): 4331-4341.
doi: 10.1210/jc.2008-1102
|
[14] |
Klopper JP, Berenz A, Hays WR, et al.
In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma[J]. Clin Cancer ResClin Cancer Res, 2008, 14(2): 589-596.
doi: 10.1158/1078-0432.CCR-07-0269
|
[15] |
Kim S, Yazici YD, Calzada G, et al.
Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice[J]. Mol Cancer TherMol Cancer Ther, 2007, 6(6): 1785-1792.
doi: 10.1158/1535-7163.MCT-06-0595
|
[16] |
Nahari D, Satchi-Fainaro RS, Chen M, et al.
Tumor cytotoxicity and endothelial Rac inhibition induced by TNP-470 in anaplastic thyroid cancer[J]. Mol Cancer TherMol Cancer Ther, 2007, 6(4): 1329-1337.
doi: 10.1158/1535-7163.MCT-06-0554
|
[17] |
Lin X, Zhu B, Liu Y, et al.
Follicular thyroid carcinoma invades venous rather than lymphatic vessels[J]. Diagn PatholDiagn Pathol, 2010, 5: 8-.
doi: 10.1186/1746-1596-5-8
|
[18] |
Hombach-KlonischS, BialekJ, RadestockY, etal.
INSL3hastumorpromoting activity in thyroid cancer[J]. Int J CancerInt J Cancer, 2010, 127(3): 521-531.
doi: 10.1002/ijc.25068
|
[19] |
Ercolino T, Lombardi A, Becherini L, et al.
The Y606C RET mutation causes a receptor gain of function[J]. Clin Endocrinol(Oxf)Clin Endocrinol(Oxf), 2008, 69(2): 253-258.
doi: 10.1111/j.1365-2265.2008.03197.x
|
[20] |
Quidville V, Segond N, Tebbi A, et al.
Anti-tumoral effect of a celecoxib low dose on a model of human medullary thyroid cancer in nude mice[J]. ThyroidThyroid, 2009, 19(6): 613-621.
doi: 10.1089/thy.2008.0194
|
[21] |
Vitagliano D, De Falco V, Tamburrino A, et al.
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells[J]. Endocr Relat CancerEndocr Relat Cancer, 2010, 18(1): 1-11.
doi: 10.1677/ERC-09-0292
|
[22] |
Chen MC, Yu CH, Wang SW, et al.
Anti-proliferative effects of evodiamine on human thyroid cancer cell line ARO[J]. J Cell BiochemJ Cell Biochem, 2010, 110(6): 1495-1503.
doi: 10.1002/jcb.22716
|
[23] |
Arcinas A, Yen TY, Kebebew E, et al.
Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns[J]. J Proteome ResJ Proteome Res, 2009, 8(8): 3958-3968.
doi: 10.1021/pr900278c
|
[24] |
Hoffmann S, Rockenstein A, Ramaswamy A, et al.
Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells[J]. Mol Cell EndocrinolMol Cell Endocrinol, 2007, 264(1-2): 74-81.
doi: 10.1016/j.mce.2006.10.009
|
[25] |
Fortin MA, Salnikov AV, Nestor M, et al.
Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2007, 34(9): 1376-1387.
doi: 10.1007/s00259-006-0346-5
|
[26] |
Leux C, Guénel P.
Risk factors of thyroid tumors: role of environmental and occupational exposures to chemical pollutants[J]. Rev Epidemiol Sante PubliqueRev Epidemiol Sante Publique, 2010, 58(5): 359-367.
doi: 10.1016/j.respe.2010.05.005
|
[27] |
Alfano RW, Leppla SH, Liu S, et al.
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma[J]. Mol Cancer TherMol Cancer Ther, 2010, 9(1): 190-201.
doi: 10.1158/1535-7163.MCT-09-0694
|
[28] |
Hombach-KlonischS, BialekJ, RadestockY, etal.
INSL3hastumorpromoting activity in thyroid cancer[J]. Int J CancerInt J Cancer, 2010, 127(3): 521-531.
doi: 10.1002/ijc.25068
|
[29] |
Zatelli MC, Tagliati F, Amodio V, et al.
Role of pituitary tumour transforming gene 1 in medullary thyroid carcinoma[J]. Anal Cell Pathol(Amst)Anal Cell Pathol(Amst), 2010, 33(5): 207-216.
|
[30] |
Henderson YC, Ahn SH, Kang Y, et al.
Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement[J]. Clin Cancer ResClin Cancer Res, 2008, 14(15): 4908-4914.
|
[31] |
Nucera C, Nehs MA, Mekel M, et al.
A novel orthotopic mouse model of human anaplastic thyroid carcinoma[J]. ThyroidThyroid, 2009, 19(10): 1077-1084.
doi: 10.1089/thy.2009.0055
|
[32] |
Kim S, Park YW, Schiff BA, et al.
An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice[J]. Clin Cancer ResClin Cancer Res, 2005, 11(5): 1713-1721.
doi: 10.1158/1078-0432.CCR-04-1908
|
[33] |
Sehiff BA, MeMurphy AB, Jasser SA, et al.
Epidermal growth factor receptor(EGFR)is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer[J]. Clin Cancer ResClin Cancer Res, 2004, 10(24): 8594-8602.
doi: 10.1158/1078-0432.CCR-04-0690
|
[34] |
Zou M, Famulski KS, Parhar RS, et al.
Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis: identification of S100 A4(Mts1)gene overexpression as a poor prognostic marker for thyroid carcinoma[J]. J Clin Endocrinol MetabJ Clin Endocrinol Metab, 2004, 89(12): 6146-6154.
doi: 10.1210/jc.2004-0418
|